The SearchVoat Forum

Emergent BioSolutions Inc. (NYSE:EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.

.. Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions..

Research suggests that there may be a link between Gulf War Syndrome and vaccinations, especially the experimental vaccine for anthrax. Here’s what Gulf War veterans should know... In addition to being exposed to various environmental hazards and toxic chemicals, Gulf War veterans were also given a large number of vaccines. Service members may have received as many as 17 vaccines in a short period of time. These vaccinations included the botulinum toxoid vaccine and anthrax vaccine, was were not yet approved by the FDA. Other vaccines included yellow fever, typhoid, cholera, hepatitis B, meningitis, whooping cough, polio, and tetanus.

Vaccinations were required by all forces, not just US troops. BioPort, now Emergent Biosolutions, was the exclusive manufacturer of BioThrax at the time, and this vaccine had proven to be effective against the bacterium that’s acquired through the skin, but not when the bacterium is inhaled. So, there was no Food and Drug Administration licensing for use against inhaled Anthrax. Therefore, all vaccinations given to military personnel were considered an “off-label” or experimental use of the vaccine....

Despite concerns about its safety, the Department of Defense mandated that all military personnel be vaccinated with BioThrax prior to deployment to Iraq or Afghanistan. They then expanded the anthrax vaccine immunization program to all US Military forces and DOD civilian contractors. With the expansion, BioPort Corp requested FDA approval for to include aerosol exposure approval, switching to intramuscular injections, and reducing the number of doses. In 1997, the DOD required that 2.5 million military personnel receive the Anthrax vaccine. By 1998, it was mandated for all civilian DOD personnel as well.

..Due to questions about the contents and safety of the vaccine; in October 2004, US District Court Judge Emmet G. Sullivan ruled that it was illegal for the federal government to mandate anthrax vaccinations. Judge Sullivan banned the Pentagon from forcing military personnel serving in Iraq, Afghanistan, South Korea, and part of Asia and Africa to get the anthrax shots without their prior consent. The military could not require the vaccine until the FDA approved it for the specific use of inhaled anthrax. However, those who refused quickly found themselves, for various other reasons, no longer in military service.

One of the ingredients found in BioThrax was squalene. Squalene, a banned chemical additive and the vaccine adjuvant, was found in blood tests of hundreds of sick Gulf War veterans. Squalene is not approved for internal human use other than in highly controlled experiments, but it has been studied for use as a tool to boost the body’s immune systems against certain diseases.

...In 2002, the General Accounting Office (GAO) conducted a study on adverse reactions of those who received anthrax vaccines in response to a large number of pilots leaving ranks. The most common reported reactions that lasted longer than 7 days were limited motion/pain in the arm, extreme fatigue, joint pain, and memory loss. Some debilitating issues that have been reported to Walter Reed Hospital include muscle and joint weakness, chronic fatigue, intense migraines, cognitive problems, and even some severe diseases such as multiple sclerosis and vision loss.

Grant topic: malaria Amt: $899,230

To isolate and manufacture Plasmodium falciparum reference strains for challenge models that represent better the global genetic diversity of this pathogen

Malaria endemic zones are characterized by apparent low incidences of coronavirus disease 2019 (COVID-19).